Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers

British Journal of Anaesthesia

Volumn 97, Issue 6, 2006, Pages 758-769

  Howard Alpe, Georgina M ^a   Sear, J W ^a   Foex, P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Biomarkers; C reactive protein; Effects; Non cardiac cardiovascular system; Surgery

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACUTE PHASE PROTEIN; ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; CREATINE KINASE; CYTOKINE; ENDOTHELIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; SELECTIN; SERUM AMYLOID A; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ACTIVITY; FUNCTIONAL STATUS; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; METHODOLOGY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PERIPHERAL VASCULAR DISEASE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL MORTALITY; SURGICAL PATIENT;

EID: 34447537928     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/ael303     Document Type: Review

References (96)

1. Adams JE, 3rd, Sicard GA, Allen BT, et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330: 670-4
2. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: Risk marker for unstable carotid plaque. J Vasc Surg 2003; 38: 1018-24
3. Andrews N, Jenkins J, Andrews G, Walker P. Using postoperative cardiac Troponin-I (cTi) levels to detect myocardial ischaemia in patients undergoing vascular surgery. Cardiovasc Surg 2001; 9: 254-65
4. Ashton CM, Petersen NJ, Wray NP, et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann Intern Med 1993; 118: 504-10
5. Auerbach A, Goldman L. Assessing and reducing the cardiac risk of noncardiac surgery. Circulation 2006; 113: 1361-76
6. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol 2005; 96: 1374-8
7. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: Basic mechanisms: Oxidation, inflammation and genetics. Circulation 1995; 91: 2488-96
8. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-42
9. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-79
10. Boralessa H, de Beer FC, Manchie A, Whitwam JG, Pepys MB. C-reactive protein in patients undergoing cardiac surgery. Anaesthesia 1986; 41: 11-5
11. Bursi F, Babuin L, Barbieri A, et al. Vascular surgery patients: perioperative and long-term risk according to the ACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur Heart J 2005; 26: 2448-56
12. Chassot PG, Delabays A, Spahn DR. Preoperative evaluation of patients with, or at risk of, coronary artery disease undergoing non-cardiac surgery. Br J Anaesth 2002; 89: 747-59
13. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002; 288: 2015-22
14. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. Cardiovasc Pathol 1999; 8: 133-9
15. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study. Circulation 2005; 112: 25-31
16. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97
17. Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: Implications regarding pathophysiology and prevention. Int J Cardiol 1996; 57: 37-44
18. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. Br Med J 2005; 331: 313-21
19. Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg 2003; 26: 381-6
20. Durazzo AES, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: A randomized trial. J Vasc Surg 2004; 39: 967-75
21. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Circulation 1996; 93: 1278-317
22. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery - executive summary a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002; 105: 1257-67
23. Filipovic M, Jeger R, Probst C, et al. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. J Am Coll Cardiol 2003; 42: 1767-76
24. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112-7
25. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84
26. Haft JI, Haik BJ, Goldstein JE, Brodyn NE. Development of significant coronary artery lesions in areas of minimal disease. A common mechanism for coronary disease progression. Chest 1988; 94: 731-6
27. Haggart PC, Adam DJ, Ludman PF, Bradbury AW. Comparison of cardiac troponin I and creatine Kinase ratios in the detection of myocardial injury after aortic surgery. Br J Surg 2001; 88: 1196-200
28. Haim M, Tanne D, Boyko, V, et al. Soluble intercellular adhesion molecule-I and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate infarction Prevention (BIP) Study. J Am Coll Cardiol 2002; 39: 1133-8
29. Haverkate E, Thompson SG, Pyke SDM, Gallimore JR, Group MBP. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-66
30. Higham H, Sear JW, Sear YM, Kemp M, Hooper RJ, Foex P. Perioperative troponin I concentration as a marker of long-term postoperative adverse cardiac outcomes - a study in high-risk surgical patients. Anaesthesia 2004; 59: 318-23
31. Hobbs SD, Yapanis M, Burns PJ, Wilmink AB, Bradbury AW, Adam DJ. Peri-operative myocardial injury in patients undergoing surgery for critical limb ischaemia. Eur J Vasc Endovasc Surg 2005; 29: 301-4
32. Howell SJ, Thompson JP, Nimmo AF, et al. Relationship between perioperative troponin elevation and other indicators of myocardial injury vascular surgery patients. Br J Anaesth 2006; 96: 303-9
33. Hunt ME, O'Malley PG, Vernalis MN, Feuerstein IM, Taylor AJ. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J 2001; 141: 206-10
34. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-32
35. Jules-Elysee K, Urban MK, Urquhart B, Milman S. Troponin I as a diagnostic marker of a perioperative myocardial infarction in the orthopedic population. J Clin Anesth 2001; 13: 556-60
36. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72
37. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116: 96-103
38. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42
39. Kowalska I, Straczkowski M, Szelachowska M, et al. Circulating E-selectin, vascular cell adhesion molecule-I and intercellular adhesion molecule-I in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism 2002; 51: 733-6
40. Landesberg G. The pathophysiology of perioperative myocardial infarction: Facts and perspectives. J Cardiothorac Vasc Anesth 2003; 17: 90-100
41. Landesberg G, Mosseri M, Shatz V, et al. Cardiac troponin after major vascular surgery: The role of perioperative ischemia, preoperative thallium scanning and coronary revascularization. J Am Coll Cardiol 2004; 44: 569-75
42. Le Manach Y, Perel A, Coriat P, Godet G, Bertrand M, Riou B. Early and delayed myocardial infarction after abdominal aortic surgery. Anesthesiology 2005; 102: 885-91
43. Lee TH, Thomas EJ, Ludwig LE, et al. Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery. Am J Cardiol 1996; 77: 1031-6
44. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291: 2092-9
45. Lubos E, Schnabel R, Rupprecht HJ, et al. Prognostic value of tissue inhibitor of metalloproteinase-I for cardiovascular death among patients with cardiovascular disease: Results from the Athero-Gene study. Eur Heart J 2006; 27: 150-6
46. Mahla E, Vicenzi MN, Schrottner B, et al. Coronary artery plaque burden and perioperative cardiac risk. Anesthesiology 2001; 95: 1133-40
47. Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. N Engl J Med 1995; 333: 1750-6
48. Martinez EA, Nass CM, Jermyn RM, et al. Intermittent cardiac troponin-I screening is an effective means of surveillance for a perioperative myocardial infarction. J Cardiothorac Vasc Anesth 2005; 19: 577-82
49. Metzler H, Gries M, Rehak P, Lang T, Fruhwald S, Toller W. Perioperative myocardial cell injury: The role of troponins. Br J Anaesth 1997; 78: 386-90
50. Montero I, Orbe J, Varo N, et al. C-reactive protein induces matrix metalloproteinase-I and -10 in human endotheliall cells: Implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-78
51. Motamed C, Motamed-Kazerounian G, Merle JC, et al. Cardiac troponin I assessment and late cardiac complications after carotid stenting or endarterectomy. J Vasc Surg 2005; 41: 769-74
52. Munzer T, Heim C, Riesen W. Perioperative myocardial infarction and cardiac complications after noncardiac surgery in patients with prior myocardial infarction. III: Troponin T - a significant diagnostic alternative in perioperative myocardial infarction? Anaesthesist 1996; 45: 225-30
53. Naito Y, Tamai S, Shingu K, et al. Responses of plasma adreno-corticotropic hormone, cortisol and cytokines during and after upper abdominal surgery. Anesthesiology 1992; 77: 426-31
54. NCEPOD. Then and now: The 2000 Report of the National Confidential Enquiry into Perioperative Deaths. K.G. Callum, eds. National Confidential Enquiry into Perioperative Deaths, 2000.
55. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med 2004; 164: 1546-51
56. Nissen SE. High-dose statins in acute coronary syndromes: Not just lipid levels. JAMA 2004; 292: 1365-7
57. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6
58. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: The Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cordiol 2005; 45: 336-42
59. Oscarsson A, Eintrei C, Anskar S, et al. Troponin T-values provide long-term prognosis in elderly patients undergoing non-cardiac surgery. Acta Anaesthesiol Scand 2004; 48: 1071-9
60. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
61. Pepys MB. C-reactive protein fifty years on. Lancet 1981; 1: 653-7
62. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-94
63. Redberg RF, Rifai N, Gee L, Ridker PM. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: Implications for coronary artery disease screening. J Am Coll Cardiol 2000; 36: 39-43
64. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9
65. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule I and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92
66. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43
67. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53
68. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72
69. Riggs TL Research and development costs for drugs. Lancet 2004; 363: 184
70. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26
71. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002; 105: 800-3
72. Rutberg H, Hakanson E, Anderberg B, Jorfeldt L, Martensson J, Schildt B. Effects of the extradural administration of morphine, or bupivacaine, on the endocrine response to upper abdominal surgery. Br J Anaesth 1984; 56: 233-8
73. Schiffrin EL. Role of endothelin-I in hypertension and vascular disease. Am J Hypertens 2001; 14: 83-95
74. Schnyder G, Flammer Y, Roffi M, Pin R, Hess OM. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 2002; 40: 1769-76
75. Schouten O, Kertai M D, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005; 95: 658-60
76. Speidl WS, Exner M, Amighi J, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26: 2294-9
77. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-6
78. Stevens RD, Burri H, Tramer MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: A quantitative systematic review. Anesth Analg 2003; 97: 623-33
79. Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Graham IM, Noble IM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000; 102: 605-10
80. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9
81. Tanne D, Haim M, Boyko V, et al. Soluble intercellular adhesion molecule-I and risk of future ischemic stroke: A nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. Stroke 2002; 33: 2182-6
82. Thygesen K, Alpert JS. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-13
83. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus. J Exp Med 1930; 52: 561-71
84. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-9
85. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976-83
86. Vainas T, Stassen FRM, de Graaf R, et al. C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events. J Vasc Surg 2005; 42: 243-51
87. Van Beneden P, Gurne O, Selvais PL, et al. Superiority of big endothelin-I and endothelin-I over natriuretic peptides in predicting survival in severe congestive heart failure: A 7-year follow-up study. J Card Fail 2004; 10: 490-5
88. Voleti B, Agrawal A. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol 2006; 43: 891-6
89. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-6
90. Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 2004; 101: 284-93
91. Wang Q, Hunt SC, Xu Q, et al. Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI family heart study. Am J Physiol Heart Circ Physiol 2006 (in press)
92. White SM. 'Death on the table'. Anaesthesia 2003; 58: 515-8
93. Witte DR, Broekmans WM, Kardinaal AF, et al. Soluble intercellular adhesion molecule I and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis 2003; 170: 147-53
94. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44: 1819-24
95. Woodward M, Lowe GD, Campbell DJ, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36: 2143-7
96. Yokoyama M, Itano Y, Katayama H, et al. The effects of continuous epidural anesthesia and analgesia on stress response and immune function in patients undergoing radical esophagectomy. Anesth Analg 2005; 101: 1521-7